Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) ...

The evolving treatment landscape in polycythemia vera (PV) is shifting from a focus on hematocrit control to a more ...

A panelist discusses how polycythemia vera (PV) is a rare myeloproliferative neoplasm (MPN) characterized by excessive red blood cell production, primarily affecting older adults with JAK2 mutations, ...

Rusfertide reduces or eliminates phlebotomy needs in polycythemia vera, improving quality of life and symptom control. The VERIFY trial showed 77% clinical response with rusfertide, compared to 33% in ...

Vanda Pharmaceuticals (VNDA)’ treatment of polycythemia vera was granted FDA orphan designation, according to a post to the agency’s website. TipRanks is the most comprehensive data set of sell side ...

Breakthrough Therapy designation complements Rusfertide’s Orphan Drug and Fast Track designations, which together confer multiple benefits to the development program U.S. New Drug Application filing ...

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved ...

SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult ...

Breakthrough designation for rusfertide was supported by positive 32-week data from the Phase 3 VERIFY study, which was presented as a late breaking abstract highlighting its practice-changing ...